Given that CTLA-4 blockade can lead to tumor regression in murine models (22, 23), multiple studies concluded with the clinical development and approval of anti-CTLA-4 monoclonal antibodies (mAb) for the treatment of patients with advanced melanoma (24, 25). The gene discussed is CTLA4; the disease is melanoma.